What's Happening?
The field of Parkinson’s disease (PD) research is undergoing a significant transition from focusing solely on symptom control to exploring disease-modifying therapies (DMTs). Traditionally, PD treatment
has centered on dopamine replacement to manage motor symptoms. However, recent scientific advances are driving efforts to develop therapies that slow or alter disease progression. These include monoclonal antibodies, small-molecule kinase inhibitors, and gene therapies targeting biological mechanisms such as alpha-synuclein aggregation and LRRK2 signaling. Despite the challenges, multiple programs are underway to generate data demonstrating the potential to slow neuronal loss and modify the disease course.
Why It's Important?
This shift in focus is crucial as PD is the fastest-growing major neurodegenerative disorder, with prevalence expected to more than double by 2050. Current treatments primarily address symptoms, but do not alter the underlying disease process. Developing DMTs could transform the management of PD by preserving neurons and potentially restoring function, offering hope for improved long-term outcomes. The integration of biomarkers for early detection and patient stratification is also enhancing research efforts, paving the way for more targeted and effective therapies. Success in this area could set a precedent for other neurodegenerative diseases.
What's Next?
Several late-stage trials are expected to report results between 2025 and 2027, marking a critical test for disease-modifying strategies in PD. These trials will focus on demonstrating the ability to slow disease progression and improve patient outcomes. The development of biomarkers for early detection and patient stratification will be essential for trial success and regulatory approval. As research progresses, the focus will likely expand to include regenerative approaches, such as cell therapy and gene-based strategies, aiming to restore dopaminergic circuitry and enhance neuronal resilience. Continued investment and collaboration will be key to advancing these promising therapies.
